These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30763908)

  • 21. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
    Hobart J; Kalkers N; Barkhof F; Uitdehaag B; Polman C; Thompson A
    Mult Scler; 2004 Feb; 10(1):41-6. PubMed ID: 14760951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
    Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contemporary study of multiple sclerosis disability in South East Wales.
    Harding KE; Ingram G; Tallantyre EC; Joseph F; Wardle M; Pickersgill TP; Willis MD; Tomassini V; Pearson OR; Robertson NP
    J Neurol Neurosurg Psychiatry; 2023 Apr; 94(4):272-279. PubMed ID: 36328420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry.
    Hughes S; Spelman T; Trojano M; Lugaresi A; Izquierdo G; Grand'maison F; Duquette P; Girard M; Grammond P; Oreja-Guevara C; Hupperts R; Boz C; Bergamaschi R; Giuliani G; Rio ME; Lechner-Scott J; van Pesch V; Iuliano G; Fiol M; Verheul F; Barnett M; Slee M; Herbert J; Kister I; Vella N; Moore F; Petkovska-Boskova T; Shaygannejad V; Jokubaitis V; McDonnell G; Hawkins S; Kee F; Gray O; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):305-10. PubMed ID: 22205675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in disability profile and quality of life in multiple sclerosis patients: a five-year longitudinal study using the Multiple Sclerosis Impact Profile (MSIP).
    Wynia K; van Wijlen AT; Middel B; Reijneveld SA; Meilof JF
    Mult Scler; 2012 May; 18(5):654-61. PubMed ID: 21965423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disability weight for each level of the Expanded Disability Status Scale in multiple sclerosis.
    Cho JY; Hong KS; Kim HJ; Kim SH; Min JH; Kim NH; Ahn SW; Park MS; An JY; Kim BJ; Kim W
    Mult Scler; 2014 Aug; 20(9):1217-23. PubMed ID: 24399825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
    Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
    J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Composite end points to assess delay of disability progression by MS treatments.
    Zhang J; Waubant E; Cutter G; Wolinsky J; Leppert D
    Mult Scler; 2014 Oct; 20(11):1494-501. PubMed ID: 24675040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The natural history of early versus late disability accumulation in primary progressive MS.
    Koch MW; Greenfield J; Javizian O; Deighton S; Wall W; Metz LM
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):615-21. PubMed ID: 25091366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychiatric comorbidity is associated with disability progression in multiple sclerosis.
    McKay KA; Tremlett H; Fisk JD; Zhang T; Patten SB; Kastrukoff L; Campbell T; Marrie RA;
    Neurology; 2018 Apr; 90(15):e1316-e1323. PubMed ID: 29523642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient reported outcomes in benign multiple sclerosis.
    Hviid LE; Healy BC; Rintell DJ; Chitnis T; Weiner HL; Glanz BI
    Mult Scler; 2011 Jul; 17(7):876-84. PubMed ID: 21372114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample.
    Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z
    J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial.
    Scott TF; You X; Foulds P
    Neurol Res; 2011 Jun; 33(5):549-52. PubMed ID: 21669126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of physical comorbidities on disability progression in multiple sclerosis.
    Zhang T; Tremlett H; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell T; Stadnyk K; Carruthers R; Wolfson C; Warren S; Marrie RA;
    Neurology; 2018 Jan; 90(5):e419-e427. PubMed ID: 29298855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study.
    Weinshenker BG; Issa M; Baskerville J
    Arch Neurol; 1996 Apr; 53(4):353-8. PubMed ID: 8929158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression.
    Truong CTL; Le HV; Kamauu AW; Holmen JR; Fillmore CL; Kobayashi MG; Wong SL
    Adv Ther; 2021 Sep; 38(9):4786-4797. PubMed ID: 34333756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.